17:33 , Jul 20, 2018 |  BC Week In Review  |  WIR Deals New Deals

Novartis in atopic dermatitis deal with MorphoSys, Galapagos

MorphoSys AG (Xetra:MOR; NASDAQ:MOR) and Galapagos N.V. (Euronext:GLPG; NASDAQ:GLPG) granted Novartis AG (NYSE:NVS; SIX:NOVN) exclusive, worldwide rights to MOR106, a mAb against IL-17C that is in Phase II testing for atopic dermatitis. MorphoSys and Galapagos...
20:37 , Jul 19, 2018 |  BC Extra  |  Company News

Novartis in atopic dermatitis deal with MorphoSys, Galapagos

MorphoSys AG (Xetra:MOR; NASDAQ:MOR) and Galapagos N.V. (Euronext:GLPG; NASDAQ:GLPG) granted Novartis AG (NYSE:NVS; SIX:NOVN) exclusive, worldwide rights to MOR106, a mAb against IL-17C that is in Phase II testing for atopic dermatitis. MorphoSys and Galapagos...
17:55 , Mar 2, 2018 |  BC Week In Review  |  Clinical News

Galapagos, MorphoSys report Phase I data for atopic dermatitis candidate

Galapagos N.V. (Euronext:GLPG; NASDAQ:GLPG) and MorphoSys AG (Xetra:MOR; Pink:MPSYY) reported pooled data from 25 patients with moderate to severe atopic dermatitis across all three dose cohorts in a Phase I trial showing that IV MOR106...
07:00 , Nov 3, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Autoimmune disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Autoimmune disease Autoimmune disease IL-17C; IL-17 receptor E (IL-17RE) Mouse studies suggest antagonizing IL-17C or its receptor, IL-17RE, could help treat autoimmune diseases. In mice with...
07:00 , Nov 3, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Autoimmune disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Autoimmune disease Autoimmune disease IL-17C; IL-17 receptor E (IL-17RE) Mouse studies suggest antagonizing IL-17C or its receptor, IL-17RE, could help treat autoimmune diseases. In mice with...